| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-16T03:00:55Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao, Yu-Yun; Wang, Shen-Yung; Lin, Shi-Ming; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG |
| 臺大學術典藏 |
2022-01-25T05:10:44Z |
Interferon �\-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu C.-J.; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; CHI-LING CHEN; Chen P.-J.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-25T05:10:33Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; CHI-LING CHEN; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-25T05:07:22Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; CHI-LING CHEN; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:29Z |
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B
|
Lin C.-L.; Liao L.-Y.; CHUN-JEN LIU; Chen P.-J.; Lai M.-Y.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:32:16Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
CHUN-JEN LIU; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; Chen P.-J.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:32:12Z |
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels
|
Lin C.-L.; Liao L.-Y.; CHUN-JEN LIU; Yu M.-W.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:58Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; CHUN-JEN LIU; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:47Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:28Z |
Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
|
Chang M.-H.; You S.-L.; Chen C.-J.; CHUN-JEN LIU; Lai M.-W.; Wu T.-C.; Wu S.-F.; Lee C.-M.; Yang S.-S.; Chu H.-C.; Wang T.-E.; Chen B.-W.; Chuang W.-L.; Soon M.-S.; Lin C.-Y.; Chiou S.-T.; Kuo H.-S.; Chen D.-S.; Yang Y.-J.; Lo G.-H.; Kong M.-S.; Wang P.-M.; Yang C.-C.; Chu C.-H.; Lin L.-H.; Chien R.-N.; Lee T.-H.; Yang K.-C.; Liao L.-Y.; Mo L.-R.; Liu J.-D.; Yang T.-H.; Lo C.-C.; Tsai M.-H.; Chou C.-H.; Cheng Y.-S. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-09-04T06:19:17Z |
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B
|
Lin C.-L.; Liao L.-Y.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:19:09Z |
Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy
|
Lin C.-L.; Liao L.-Y.; Wang C.-S.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:19:05Z |
Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B
|
Lin C.-L.; Liao L.-Y.; Wang C.-S.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:18:58Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu C.-J.; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; Chen P.-J.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:18:52Z |
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels
|
Lin C.-L.; Liao L.-Y.; Liu C.-J.; Yu M.-W.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:51Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; JIA-HORNG KAO; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T05:16:29Z |
Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
|
Lin C.-L.; Tseng K.-C.; Chen K.-Y.; Liao L.-Y.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-01T01:54:03Z |
Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma
|
Yen C.-H.; Lu Y.-C.; Li C.-H.; Lee C.-M.; Chen C.-Y.; Cheng M.-Y.; Huang S.-F.; Chen K.-F.; ANN-LII CHENG; Liao L.-Y.; Lee Y.-H.W.; Chen Y.-M.A. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-03T07:10:53Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-07-03T03:35:49Z |
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B
|
Lin C.-L.; Liao L.-Y.; Liu C.-J.; PEI-JER CHEN; Lai M.-Y.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:35:36Z |
Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy
|
Lin C.-L.; Liao L.-Y.; Wang C.-S.; PEI-JER CHEN; Lai M.-Y.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:35:25Z |
Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B
|
Lin C.-L.; Liao L.-Y.; Wang C.-S.; PEI-JER CHEN; Lai M.-Y.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:35:14Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu C.-J.; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; PEI-JER CHEN; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:35:08Z |
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels
|
Lin C.-L.; Liao L.-Y.; Liu C.-J.; Yu M.-W.; PEI-JER CHEN; Lai M.-Y.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:34:42Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; PEI-JER CHEN; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:34:41Z |
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
|
Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN; Chen L.-T. |
| 臺大學術典藏 |
2021-07-03T03:34:20Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-05-24T07:20:50Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; CHEN-HUA LIU; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-05-24T07:20:44Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; CHEN-HUA LIU; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-04-26T01:47:25Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; MING-CHIH HO; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-03-09T01:47:46Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; TUNG-HUNG SU; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-02-25T07:00:59Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Yu-Yun Shao;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Hsu C.;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T08:01:12Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Chiun Hsu;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Chiun Hsu; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-01-04T07:32:20Z |
Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
|
You S.-L.; MEI-HWEI CHANG; Chen C.-J.; Liu C.-J.; Lai M.-W.; Wu T.-C.; Wu S.-F.; Lee C.-M.; Yang S.-S.; Chu H.-C.; Wang T.-E.; Chen B.-W.; Chuang W.-L.; Soon M.-S.; Lin C.-Y.; Chiou S.-T.; Kuo H.-S.; Chen D.-S.; Yang Y.-J.; Lo G.-H.; Kong M.-S.; Wang P.-M.; Yang C.-C.; Chu C.-H.; Lin L.-H.; Chien R.-N.; Lee T.-H.; Yang K.-C.; Liao L.-Y.; Mo L.-R.; Liu J.-D.; Yang T.-H.; Lo C.-C.; Tsai M.-H.; Chou C.-H.; Cheng Y.-S. |
| 臺大學術典藏 |
2021 |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Tseng J.-H.; Ho M.-C.; Liao L.-Y.; Liang J.-D.; Wang C.-K.; Lee W.-C.; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Lee R.-C.; Liang P.-C.; Huang K.-W.; Hu J.-T.; Kee K.-M.; Lin C.-L.; Lu S.-N.; Wang J.-H.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2020-12-28T08:14:10Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Yen-Hsuan Ni;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Wang P.-M.; Chao Y.; Chen L.-T.; Hsu C.; Cheng A.-L.; Lin C.-C.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-08-11T08:36:42Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Po-Chin Liang;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Huo T.-I.; Liao L.-Y.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Lu S.-N. |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Huang Y.-H.; Lee K.-T.; Wang C.-C.; Chau G.-Y.; Lee W.-C.; Ting C.-T.; Lee P.-H.; Wu C.-C.; Huo T.-I.; Liao L.-Y.; Huang S.-F.; Hung C.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Chia-Hsien Cheng;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-03-31T06:51:17Z |
Method development and validation for the high-performance liquid chromatography assay of gastrodin in water extracts from different sources of Gastrodia elata Blume
|
Chen W.-C.;Lai Y.-S.;Kuan-Hung Lu;Lin S.-H.;Liao L.-Y.;Ho C.-T.;Sheen L.-Y.; Chen W.-C.; Lai Y.-S.; KUAN-HUNG LU; Lin S.-H.; Liao L.-Y.; Ho C.-T.; Sheen L.-Y. |
| 臺大學術典藏 |
2020-02-19T09:33:41Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ming-Chih Ho;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group;Surveillance Group;Diagnosis Group;Staging Group;Surgery Group;Tace/Tare/Hai Group;Target Therapy/Systemic Therapy Group;Radiotherapy Group;Prevention Group;Drafting Group; Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; MING-CHIH HO; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group |
| 臺大學術典藏 |
2020-01-21T01:20:47Z |
Truncating the putative membrane association region circumvents the difficulty of expressing hepatitis C virus protein E1 in Escherichia coli
|
BO-SHIUN YAN; Liao L.-y.; Leou K.; Chang Y.-C.; Syu W.-J. |
| 臺大學術典藏 |
2018-09-10T14:58:57Z |
The development of stream temperature model in a mountainous river of Taiwan
|
Tung, C.-P.;Lee, T.-Y.;Huang, J.-C.;Perng, P.-W.;Kao, S.-J.;Liao, L.-Y.; Tung, C.-P.; Lee, T.-Y.; Huang, J.-C.; Perng, P.-W.; Kao, S.-J.; Liao, L.-Y.; JR-CHUAN HUANG; CHING-PIN TUNG |
| 臺大學術典藏 |
2018-09-10T06:00:47Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu, C.-J.;Lai, M.-Y.;Chao, Y.-C.;Liao, L.-Y.;Yang, S.-S.;Hsiao, T.-J.;Hsieh, T.-Y.;Lin, C.-L.;Hu, J.-T.;Chen, C.-L.;Chen, P.-J.;Kao, J.-H.;Chen, D.-S.; CHUN-JEN LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T05:25:11Z |
Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B
|
Lin, C.-L.; Liao, L.-Y.; Wang, C.-S.; Chen, P.-J.; Lai, M.-Y.; Chen, D.-S.; Kao, J.-H.; PEI-JER CHEN; DING-SHINN CHEN; JIA-HORNG KAO |
